Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Humanm Antibodys:ABGX,MEDX, CAT , Morphosys.... -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (3)	1/24/2000 5:46:00 PM
From: Mel Spivak	Read Replies (2) \| Respond to of 23

MEDX @ 71 New Dain Raucher Analyst Report -Target 106 Dain Rauscher by: Theczecho98 (46/M/NY) 1/24/00 4:49 pm Msg: 15480 of 15489 Paraphrased Excerpts from todays release: The potential of the Kirin and MEDX technologies is substantial. AS noted following the Kirin Announcement, MEDX has put to rest any outstanding issues relating to its technology for developing fully human therapeutic antibodies.. Perceptions has held that ABGX, MEDX's only competitor in this field has maintained a technological edge as its X-Mouse employs approx 34 variable region genes for the generation of fully human anitibodies in comparison to MEDX's 7 genes. We believe that this discrepancy has not, in fact, provided a tech advantage for ABGX. Be that as it may, MEDX, thru its alliance with Kirin now has access to a system that contains 87 variable gene regions, representing the entirety of the human genes associated with the creation of antibodies. AS SUCH, THE PERCEPTION OF ANY TECH ADVANTAGE ON THE PART OF ABGX HAS BEEN ELIMINATED, AND MAY, IF ACCOUNTING PROCEDURES PREVAIL, INDICATE THAT THE ADVANTAGE ACTUALLY RESIDES WITH MEDAREX. Strategic development collaborations for pipeline drugs has allowed MEDX to focus on the HuMab business. These alliances provide MEDX with upfront license fees, milestone payments, and potential royalties on sales of drugs approved for commercialization. Importantly, these alliances also allow MEDX to focus on the heart of their business, the HuMab technology. So what does the future hold for MEDX?? Taking into account what the company has accomplished in the recent past, we believe that the prospects for MEDX are significant. The Kirin alliance has provided MEDX with a leading technology platform, eliminated past perception issues relating to the HuMab technology, and paved the way for additional collaborations. We estimate that the combination of the Kirin tech with the HuMab platform could yield collaborations up to $ 350 mil. By entering into development agreements for its pipeline drugs, MEDX has not only secured solid cash in-flows, but also attenuated the burden of its bi-specific platform.. This should, in our view, allow the company to refocus additional attention on leveraging the Mouse platforms (Kirin's and MEDX) into financially lucrative corporate collaborations. We re-iterate our strong buy-Speculative Rating and are taking this opportunity to raise our price target to $106 from $66. Mel: This is a cleaned up version of what was posted on Yahoo. 106